The Latest Breaking News from biotechnology

Among the recent momentum standouts in the biotechnology sector, four stocks have drawn considerable investor attention, entering the top 10th percentile of momentum-ranked stocks based on decisive week-on-week percentile gains.

TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.

Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in autoimmune diseases showed encouraging signs.

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) are up Thursday after the biotechnology company raised guidance for four key financial metrics and shared positive sales performance for this past quarter.

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.

As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.

Investors are increasingly looking to biotechnology companies for potential breakthroughs and profitable returns, as the sector shows resilience and growth amid broader market volatility. Within this landscape, Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is capturing attention with its promising drug portfolio and financial performance.

Among biotechnology stocks, several names have hovered around the top momentum percentile this week, signaling robust bullish activity and potential for short-term gains.

As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced therapeutic platforms. Kite Pharma, a Gilead Sciences Inc. company (NASDAQ:GILD) on Thursday agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR…

The biotechnology sector is experiencing a surge in innovation as companies develop advanced therapies to address complex diseases. This wave of progress is particularly evident in the development of novel treatments for autoimmune disorders, where cutting-edge cell therapies hold promise to transform patient care.